Moore becomes CSO at Zymeworks
Plus new COO and CBO at Cellino, and updates from Aclaris, Amryt, TCR2 and more
Zymeworks Inc. (NYSE:ZYME) hired Paul Moore as CSO, effective July 18. Moore was VP, cell biology and immunology at MacroGenics Inc. (NASDAQ:MGNX) and director of cell biology at Celera Corp. In January, Zymeworks raised $100 million and hired Kenneth Galbraith to succeed longtime CEO Ali Tehrani, cut costs, and focus on pivotal studies of zanidatamab in biliary tract cancer and gastroesophageal adenocarcinoma.
Autonomous cell therapy technology platform company Cellino Biotech Inc. hired Abhijit Kulkarni as COO and Paulette Dillon as SVP and CBO. Kulkarni was global VP of R&D and technology for neuromodulation and pelvic health and head of the Neuromodulation Technology Development Center of Medtronic plc (NYSE:MDT). Dillon was SVP of corporate development of Atreca Inc. (NASDAQ:BCEL), an antibody company she co-founded. ...